Rhenman & Partners Asset Management AB boosted its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 31.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 475,872 shares of the biopharmaceutical company’s stock after purchasing an additional 114,193 shares during the quarter. Rhenman […]

Related Keywords

United States , Dustins Sjuts , Piper Sandler , Tobin Schilke , Quest Partners , Capstone Investment Advisors , Nasdaq , Revance Therapeutics Inc , Needham Company , Exchange Commission , Goldman Sachs Group , Asset Management Inc , Partners Asset Management , Revance Therapeutics , Free Report , Management Inc , Investment Advisors , Investment Management , Trexquant Investment , Get Free Report , President Dustin , Visit Holdingschannel , Revance Therapeutics Daily ,